{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:30:53Z","timestamp":1790713853450,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"crossref","award":["K08NS097624"],"award-info":[{"award-number":["K08NS097624"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Resource for Translational and Developmental Proteomics","award":["P41 GM108569"],"award-info":[{"award-number":["P41 GM108569"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CCSG P30 CA060553"],"award-info":[{"award-number":["CCSG P30 CA060553"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric brainstem tumor. Most DIPGs harbor a histone H3 mutation, which alters histone post-translational modification (PTM) states and transcription. Here, we employed quantitative proteomic analysis to elucidate the impact of the H3.3K27M mutation, as well as radiation and bromodomain inhibition (BRDi) with JQ1, on DIPG PTM profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed targeted mass spectrometry on H3.3K27M mutant and wild-type tissues (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) and cell lines (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 29.2 and 26.4% of total H3.3K27 peptides were H3.3K27M in mutant DIPG tumor cell lines and tissue specimens, respectively. Significant differences in modification states were observed in H3.3K27M specimens, including at H3K27, H3K36, and H4K16. In addition, H3.3K27me1 and H4K16ac were the most significantly distinct modifications in H3.3K27M mutant tumors, relative to wild-type. Further, H3.3K36me2 was the most abundant co-occurring modification on the H3.3K27M mutant peptide in DIPG tissue, while H4K16ac was the most acetylated residue. Radiation treatment caused changes in PTM abundance in vitro, including increased H3K9me3. JQ1 treatment resulted in increased mono- and di-methylation of H3.1K27, H3.3K27, H3.3K36 and H4K20 in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, our findings provide insight into the effects of the H3K27M mutation on histone modification states and response to treatment, and suggest that H3K36me2 and H4K16ac may represent unique tumor epigenetic signatures for targeted DIPG therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-020-01773-x","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T07:05:53Z","timestamp":1606287953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma"],"prefix":"10.1186","volume":"39","author":[{"given":"Shejuan","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie M.","family":"Camarillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Yi-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline A.","family":"Zoltek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Behbahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Kambhampati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil L.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-2771","authenticated-orcid":false,"given":"Amanda M.","family":"Saratsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"Suppl 10","key":"1773_CR1","doi-asserted-by":"publisher","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","volume":"16","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, et al. Alex's lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology. 2015;16(Suppl 10):x1\u2013x36.","journal-title":"Neuro-Oncology"},{"key":"1773_CR2","doi-asserted-by":"publisher","unstructured":"Kasper LH, Baker SJ. Invited review: emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas. Neuropathol Appl Neurobiol. 2020;46(1):73\u201385. https:\/\/doi.org\/10.1111\/nan.12591.","DOI":"10.1111\/nan.12591"},{"issue":"1","key":"1773_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00263825","volume":"7","author":"IA Langmoen","year":"1991","unstructured":"Langmoen IA, Lundar T, Storm-Mathisen I, Lie SO, Hovind KH. Management of pediatric pontine gliomas. Childs Nerv Syst. 1991;7(1):13\u20135.","journal-title":"Childs Nerv Syst"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fonc.2013.00110","volume":"3","author":"T Dasgupta","year":"2013","unstructured":"Dasgupta T, Haas-Kogan DA. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol. 2013;3:110.","journal-title":"Front Oncol"},{"issue":"9","key":"1773_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1101\/gad.217778.113","volume":"27","author":"KM Chan","year":"2013","unstructured":"Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013;27(9):985\u201390.","journal-title":"Genes Dev"},{"issue":"5","key":"1773_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","volume":"35","author":"B Krug","year":"2019","unstructured":"Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, et al. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M Gliomas. Cancer Cell. 2019;35(5):782\u201397 e788.","journal-title":"Cancer Cell"},{"issue":"4","key":"1773_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493\u2013500.","journal-title":"Nat Med"},{"issue":"5","key":"1773_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013;24(5):660\u201372.","journal-title":"Cancer Cell"},{"key":"1773_CR9","doi-asserted-by":"publisher","unstructured":"Igolkina AA, Zinkevich A, Karandasheva KO, Popov AA, Selifanova MV, Nikolaeva D, Tkachev V, Penzar D, Nikitin DM, Buzdin A. H3K4me3, H3K9ac, H3K27ac, H3K27me3 and H3K9me3 Histone Tags Suggest Distinct Regulatory Evolution of Open and Condensed Chromatin Landmarks. Cells. 2019;8(9):1034. https:\/\/doi.org\/10.3390\/cells8091034.","DOI":"10.3390\/cells8091034"},{"issue":"5","key":"1773_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bpa.12042","volume":"23","author":"S Venneti","year":"2013","unstructured":"Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M, Thompson CB, Judkins AR. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013;23(5):558\u201364.","journal-title":"Brain Pathol"},{"issue":"4","key":"1773_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s40495-018-0141-6","volume":"4","author":"YCE Wan","year":"2018","unstructured":"Wan YCE, Liu J, Chan KM. Histone H3 mutations in Cancer. Curr Pharmacol Rep. 2018;4(4):292\u2013300.","journal-title":"Curr Pharmacol Rep"},{"issue":"98","key":"1773_CR12","doi-asserted-by":"publisher","first-page":"37112","DOI":"10.18632\/oncotarget.26430","volume":"9","author":"T Huang","year":"2018","unstructured":"Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget. 2018;9(98):37112\u201324.","journal-title":"Oncotarget"},{"issue":"6134","key":"1773_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857\u201361.","journal-title":"Science"},{"issue":"7265","key":"1773_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature08398","volume":"461","author":"R Margueron","year":"2009","unstructured":"Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, Voigt P, Martin SR, Taylor WR, De Marco V, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature. 2009;461(7265):762\u20137.","journal-title":"Nature"},{"issue":"1\u20132","key":"1773_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","volume":"647","author":"JA Simon","year":"2008","unstructured":"Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647(1\u20132):21\u20139.","journal-title":"Mutat Res"},{"issue":"6200","key":"1773_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1126\/science.1255104","volume":"345","author":"HM Herz","year":"2014","unstructured":"Herz HM, Morgan M, Gao X, Jackson J, Rickels R, Swanson SK, Florens L, Washburn MP, Eissenberg JC, Shilatifard A. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science. 2014;345(6200):1065\u201370.","journal-title":"Science"},{"issue":"1","key":"1773_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-019-0727-1","volume":"7","author":"J Qi","year":"2019","unstructured":"Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, et al. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. Acta Neuropathol Commun. 2019;7(1):75.","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"1773_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.3716","volume":"20","author":"R Hashizume","year":"2014","unstructured":"Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20(12):1394\u20136.","journal-title":"Nat Med"},{"issue":"3","key":"1773_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11060-012-0973-6","volume":"110","author":"R Hashizume","year":"2012","unstructured":"Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, et al. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neuro-Oncol. 2012;110(3):305\u201313.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"1773_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nprot.2007.106","volume":"2","author":"BA Garcia","year":"2007","unstructured":"Garcia BA, Mollah S, Ueberheide BM, Busby SA, Muratore TL, Shabanowitz J, Hunt DF. Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat Protoc. 2007;2(4):933\u20138.","journal-title":"Nat Protoc"},{"issue":"12","key":"1773_CR21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1007\/s13361-019-02255-x","volume":"30","author":"JM Camarillo","year":"2019","unstructured":"Camarillo JM, Swaminathan S, Abshiru NA, Sikora JW, Thomas PM, Kelleher NL. Coupling fluorescence-activated cell sorting and targeted analysis of histone modification profiles in primary human leukocytes. J Am Soc Mass Spectrom. 2019;30(12):2526\u201334.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"4","key":"1773_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00401-019-01975-4","volume":"137","author":"AB Silveira","year":"2019","unstructured":"Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, et al. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol. 2019;137(4):637\u201355.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1773_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00401-014-1319-6","volume":"128","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573\u201381.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1773_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pages M, Taylor KR, Saulnier P, Lacroix L, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130(6):815\u201327.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1773_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124(3):439\u201347.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1773_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic Pontine Glioma. Cancer Cell. 2017;32(4):520\u201337 e525.","journal-title":"Cancer Cell"},{"issue":"6","key":"1773_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.molcel.2019.08.030","volume":"76","author":"S Nagaraja","year":"2019","unstructured":"Nagaraja S, Quezada MA, Gillespie SM, Arzt M, Lennon JJ, Woo PJ, Hovestadt V, Kambhampati M, Filbin MG, Suva ML, et al. Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state. Mol Cell. 2019;76(6):965\u201380 e912.","journal-title":"Mol Cell"},{"issue":"6","key":"1773_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00401-013-1218-2","volume":"127","author":"AM Saratsis","year":"2014","unstructured":"Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B, Hall J, Raabe EH, An P, Weingart M, et al. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol. 2014;127(6):881\u201395.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1773_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","volume":"164","author":"D Sturm","year":"2016","unstructured":"Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060\u201372.","journal-title":"Cell"},{"issue":"5","key":"1773_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00401-014-1338-3","volume":"128","author":"S Venneti","year":"2014","unstructured":"Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128(5):743\u201353.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1773_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","volume":"36","author":"JN Anastas","year":"2019","unstructured":"Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, et al. Re-programing chromatin with a Bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell. 2019;36(5):528\u201344 e510.","journal-title":"Cancer Cell"},{"issue":"6","key":"1773_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","volume":"139","author":"D Castel","year":"2020","unstructured":"Castel D, Kergrohen T, Tauziede-Espariat A, Mackay A, Ghermaoui S, Lechapt E, Pfister SM, Kramm CM, Boddaert N, Blauwblomme T, et al. Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathol. 2020;139(6):1109\u201313.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"1773_CR33","doi-asserted-by":"publisher","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","volume":"4","author":"JM Stafford","year":"2018","unstructured":"Stafford JM, Lee CH, Voigt P, Descostes N, Saldana-Meyer R, Yu JR, Leroy G, Oksuz O, Chapman JR, Suarez F, et al. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv. 2018;4(10):eaau5935.","journal-title":"Sci Adv"},{"issue":"3","key":"1773_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.molcel.2011.03.025","volume":"42","author":"FW Schmitges","year":"2011","unstructured":"Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, Aiwazian J, Sack R, Hess D, Li L, Zhou S, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell. 2011;42(3):330\u201341.","journal-title":"Mol Cell"},{"issue":"10","key":"1773_CR35","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1074\/jbc.M110.194027","volume":"286","author":"W Yuan","year":"2011","unstructured":"Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem. 2011;286(10):7983\u20139.","journal-title":"J Biol Chem"},{"issue":"35","key":"1773_CR36","doi-asserted-by":"publisher","first-page":"13750","DOI":"10.1074\/jbc.RA118.004274","volume":"293","author":"NP Coussens","year":"2018","unstructured":"Coussens NP, Kales SC, Henderson MJ, Lee OW, Horiuchi KY, Wang Y, Chen Q, Kuznetsova E, Wu J, Chakka S, et al. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2. J Biol Chem. 2018;293(35):13750\u201365.","journal-title":"J Biol Chem"},{"issue":"15","key":"1773_CR37","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s00018-019-03144-y","volume":"76","author":"J Li","year":"2019","unstructured":"Li J, Ahn JH, Wang GG. Understanding histone H3 lysine 36 methylation and its deregulation in disease. Cell Mol Life Sci. 2019;76(15):2899\u2013916.","journal-title":"Cell Mol Life Sci"},{"key":"1773_CR38","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ejmech.2018.08.026","volume":"157","author":"R Zhang","year":"2018","unstructured":"Zhang R, Wang J, Zhao L, Liu S, Du D, Ding H, Chen S, Yue L, Liu YC, Zhang C, et al. Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening. Eur J Med Chem. 2018;157:867\u201376.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1773_CR39","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1038\/s41467-019-10324-8","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Jang Y, Lee JE, Ahn J, Xu L, Holden MR, Cornett EM, Krajewski K, Klein BJ, Wang SP, et al. Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF. Nat Commun. 2019;10(1):2314.","journal-title":"Nat Commun"},{"issue":"24","key":"1773_CR40","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2010.33.3757","volume":"29","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3316\u201321.","journal-title":"J Clin Oncol"},{"key":"1773_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2017.10.013","volume":"120","author":"HS Gwak","year":"2017","unstructured":"Gwak HS, Park HJ. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol. 2017;120:111\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1773_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD. DIPG in children - what can we learn from the past? Front Oncol. 2015;5:237.","journal-title":"Front Oncol"},{"issue":"15","key":"1773_CR43","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1093\/nar\/gkf467","volume":"30","author":"M Gulston","year":"2002","unstructured":"Gulston M, Fulford J, Jenner T, de Lara C, O'Neill P. Clustered DNA damage induced by gamma radiation in human fibroblasts (HF19), hamster (V79-4) cells and plasmid DNA is revealed as Fpg and nth sensitive sites. Nucleic Acids Res. 2002;30(15):3464\u201372.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1773_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccell.2019.01.020","volume":"35","author":"J Ma","year":"2019","unstructured":"Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances Glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 2019;35(3):504\u201318 e507.","journal-title":"Cancer Cell"},{"issue":"14","key":"1773_CR45","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1158\/0008-5472.CAN-17-3691","volume":"78","author":"S Pal","year":"2018","unstructured":"Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, et al. Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated DNA damage response to Radiosensitize pediatric high-grade Gliomas. Cancer Res. 2018;78(14):4007\u201321.","journal-title":"Cancer Res"},{"key":"1773_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","volume":"58","author":"RL Bennett","year":"2018","unstructured":"Bennett RL, Licht JD. Targeting epigenetics in Cancer. Annu Rev Pharmacol Toxicol. 2018;58:187\u2013207.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7794","key":"1773_CR47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","volume":"578","author":"EJ Faivre","year":"2020","unstructured":"Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, Zhang L, Bui MH, Sheppard GS, Wang L, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578(7794):306\u201310.","journal-title":"Nature"},{"issue":"7788","key":"1773_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-019-1842-7","volume":"577","author":"L Wan","year":"2020","unstructured":"Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, Carroll TS, Li Y, Feng L, Chen G, et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature. 2020;577(7788):121\u20136.","journal-title":"Nature"},{"issue":"7472","key":"1773_CR49","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature12751","volume":"502","author":"K Helin","year":"2013","unstructured":"Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502(7472):480\u20138.","journal-title":"Nature"},{"issue":"13","key":"1773_CR50","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1074\/jbc.M113.523019","volume":"289","author":"M Jung","year":"2014","unstructured":"Jung M, Philpott M, Muller S, Schulze J, Badock V, Eberspacher U, Moosmayer D, Bader B, Schmees N, Fernandez-Montalvan A, et al. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem. 2014;289(13):9304\u201319.","journal-title":"J Biol Chem"},{"issue":"12","key":"1773_CR51","doi-asserted-by":"publisher","first-page":"a018663","DOI":"10.1101\/cshperspect.a018663","volume":"6","author":"J Qi","year":"2014","unstructured":"Qi J. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harb Perspect Biol. 2014;6(12):a018663.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7327","key":"1773_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"5","key":"1773_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, et al. Transcriptional dependencies in diffuse intrinsic Pontine Glioma. Cancer Cell. 2017;31(5):635\u201352 e636.","journal-title":"Cancer Cell"},{"issue":"4","key":"1773_CR54","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","volume":"129","author":"A Barski","year":"2007","unstructured":"Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823\u201337.","journal-title":"Cell"},{"issue":"10","key":"1773_CR55","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.18632\/aging.101572","volume":"10","author":"A Svobodova Kovarikova","year":"2018","unstructured":"Svobodova Kovarikova A, Legartova S, Krejci J, Bartova E. H3K9me3 and H4K20me3 represent the epigenetic landscape for 53BP1 binding to DNA lesions. Aging (Albany NY). 2018;10(10):2585\u2013605.","journal-title":"Aging (Albany NY)"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-020-01773-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T07:47:55Z","timestamp":1606290475000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-01773-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-51227\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-51227\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-51227\/v2","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pediatric glioma tumor tissue specimens were collected postmortem in accordance to Children\u2019s National Medical Center Institutional Protocol (IRB #Pro00001339). H3.3K27 wild-type (WT) adult glioma tumor tissue specimens (<i>n<\/i>\u2009=\u20092), and one non-tumor frontal lobe tissue specimen from a patient with focal cortical dysplasia, were collected during the course of treatment for the Nervous System Tumor Bank at Northwestern University, in accordance to Northwestern University IRB (STU00095863). Proteomic analysis was conducted with approval from the Northwestern University IRB (STU00202063).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}